Showing posts with label Europe. Show all posts
Showing posts with label Europe. Show all posts

Friday, 24 November 2017

Patient Engagement Solutions Market by Component, Delivery Mode, Applications & End User - 2022




The key factors driving the growth of this market include the rise in aging population, increasing burden of chronic diseases, and focus of patients on self-managing their care has led to an increase in the adoption of patient engagement solutions globally. However, in spite of the numerous benefits certain barriers such as security of patient data and lack of interoperability are restraining the growth of this market.

By component, the software segment accounted for the largest share of the market in 2017
On the basis of component, the patient engagement solutions market is broadly segmented into software, hardware, and services. In 2017, The software segment is estimated to account for the largest share of the global patient engagement solutions market. However, the market for the services (including services for consulting, storage, implementation of solutions, training, maintenance, and regular up gradation of technology) is expected to grow at the highest CAGR during the forecast period.

By delivery mode, the on-premise segment held the largest market share in 2017
On the basis of delivery mode, the patient engagement solutions market is further classified into on-premise and cloud-based models. In 2017, the on-premise delivery mode is expected to account for the largest share of the global patient engagement solutions market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=105975994

However, the cloud-based solutions market is projected to register the highest CAGR during the forecast period. The ability to access computing and storage resources swiftly when needed, without the requirement for a large technical staff, is one of the reasons that is driving the market growth of the cloud-based delivery mode.

By application, the health management segment held the largest market share in 2017
Based on application, the patient engagement solutions market is further segmented into health management, social and behavioral management, home health management, and financial health. In 2017, the health management segment is expected to account for the largest share and is expected to register the highest CAGR during the forecast period. Providers encouraging patients to adopt these tools as it saves a lot of time for the providers as well as increase patient compliance for care is the major factor driving the growth of this segment.

North America dominated the market in 2017
North America accounted for the largest share of the patient engagement solutions market in 2016, followed by Europe. Federal mandates’ focus on Meaningful Use of Healthcare IT, need to curb rising healthcare cost and reduce hospital readmissions, rising number of accountable care organizations (ACO) as end users for patient engagement platforms, rising aging population in the US and Canada’s efforts to enhance healthcare delivery and digital health measures in Canada will also drive market growth during the forecast period.
Patient Engagement Solutions Market

Patient Engagement Solutions Market

Factors such as growing demand for advanced healthcare solutions and efficient healthcare delivery in Germany, role of NHS in the UK, implementation of the Dossier Médical Personnel (DMP) in France, and rising number of initiatives to improve care coordination in RoE are expected to boost the adoption of patient engagement solutions in these countries.

The key players in the market include McKesson Corporation (US), Allscripts (US), IBM (US), athenahealth (US), Cerner Corporation (US), and Orion Health (New Zealand).

Mycoplasma Testing Market by Product & Services, Technique, Application and End User - 2022

Factors driving the growth of this market are the rapid growth in the pharmaceutical and biotechnology industries, R&D investments and government support. Mycoplasma testing is carried out in the research and production of all biopharmaceutical products. Growth in the pharmaceutical and biotechnology sector across the globe serves as a direct driver for associated markets such as mycoplasma testing.

Kits & reagent is expected to dominate the market in 2017

On the basis of products, the mycoplasma testing market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to dominate the global mycoplasma testing market in 2017. The frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques are key factors driving the growth of this segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=136509856

PCR technique are estimated to command the largest market share in 2017

Based on technique, the mycoplasma testing market is segmented into PCR, ELISA, direct assays, indirect assays, DNA staining, microbial culture techniques, and enzymatic methods. In 2017, the PCR technique segment is expected to account for the largest share of the mycoplasma testing market, by technique. The high acceptance rate of PCR due to the accuracy, speed, and flexibility provided by this technique in life sciences research is one of the major factors driving this segment.

Mycoplasma Testing Market

Mycoplasma Testing Market 



North America to account for the major market share in 2017

Based on region, the mycoplasma testing market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the mycoplasma testing market in 2017 on account of the high adoption rate of novel technologies and a large number of life science research studies conducted in this region.

Key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.), InvivoGen (U.S.), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd., WuXi AppTec (U.S.), Norgen Biotek Corp. (Canada), Agilent Technologies (U.S.), Biotools, B & M Labs, S.A (Spain), Eurofins Scientific (Luxembourg), Gibraltar Laboratories (U.S.), GeneCopoeia, Inc. (U.S.), GenBio (Canada), Hylabs (Israel), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (U.S.), Sartorius AG (Germany), Savyon Diagnostics (Israel), and ScienCell Research Laboratories, Inc. (Canada).

Source : https://www.prnewswire.com/news-releases/english-releases/mycoplasma-testing-market-worth-9434-million-usd-by-2022-628381673.html